Emergent BioSolutions will host a conference call on October 29, 2025, to discuss Q3 financial results.
Quiver AI Summary
Emergent BioSolutions Inc. will host a conference call on October 29, 2025, at 5:00 PM eastern time to discuss its financial results for the third quarter of 2025. Interested participants can access the call via a live webcast on the company's Investors page or register for telephone participation to receive joining details. A replay of the call will be available afterward on the same page. Emergent BioSolutions is dedicated to protecting public health and has worked for over 25 years to address health threats such as smallpox, Ebola, and opioid overdoses. For more information, visit their website or follow them on social media platforms.
Potential Positives
- Emergent BioSolutions will provide a financial update for the third quarter of 2025, indicating ongoing transparency and communication with stakeholders.
- The conference call offers multiple access options, including a live webcast and telephone participation, enhancing engagement with investors.
- The company emphasizes its long-standing commitment to public health, positioning itself as a key player in addressing significant health threats.
Potential Negatives
- The press release does not provide any information about the company's third-quarter financial performance, which may raise concerns among investors about potential negative results.
FAQ
When is the Emergent BioSolutions conference call?
The Emergent BioSolutions conference call is scheduled for Wednesday, October 29, 2025, at 5:00 pm Eastern Time.
How can I access the live conference call?
You can access the live conference call via webcast on the Investors page of Emergent’s website or by phone after registering.
What information will be discussed during the call?
The conference call will discuss Emergent BioSolutions’ financial results for the third quarter of 2025.
Is there a way to listen to the conference call after it ends?
Yes, a replay of the conference call will be available on the Investors page of Emergent’s website.
Who can I contact for media inquiries?
For media inquiries, you can contact Assal Hellmer, Vice President of Communications, at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EBS Insider Trading Activity
$EBS insiders have traded $EBS stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:
- DONALD W DEGOLYER sold 7,844 shares for an estimated $67,830
- KATHRYN C ZOON sold 7,086 shares for an estimated $62,852
- KEITH KATKIN sold 7,844 shares for an estimated $49,417
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EBS Hedge Fund Activity
We have seen 94 institutional investors add shares of $EBS stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 2,525,313 shares (+137.6%) to their portfolio in Q2 2025, for an estimated $16,111,496
- OAK HILL ADVISORS LP added 2,500,000 shares (+224.5%) to their portfolio in Q2 2025, for an estimated $15,950,000
- MILLENNIUM MANAGEMENT LLC removed 1,747,056 shares (-69.8%) from their portfolio in Q2 2025, for an estimated $11,146,217
- QUBE RESEARCH & TECHNOLOGIES LTD removed 740,415 shares (-68.1%) from their portfolio in Q2 2025, for an estimated $4,723,847
- GEODE CAPITAL MANAGEMENT, LLC added 666,708 shares (+108.9%) to their portfolio in Q2 2025, for an estimated $4,253,597
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 605,576 shares (-71.3%) from their portfolio in Q2 2025, for an estimated $3,863,574
- PACER ADVISORS, INC. added 556,730 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,551,937
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$EBS Analyst Ratings
Wall Street analysts have issued reports on $EBS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/03/2025
To track analyst ratings and price targets for $EBS, check out Quiver Quantitative's $EBS forecast page.
Full Release
GAITHERSBURG, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, October 29, 2025, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2025.
Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
A replay of the call can be accessed from the Investors page of Emergent’s website.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our
website
and follow us on
LinkedIn
,
X
,
Instagram
,
Apple Podcasts
and
Spotify
.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
[email protected]
Media Contact:
Assal Hellmer
Vice President, Communications
[email protected]
